mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2022-5-7-12mrj-1339Research ArticleЛЕКЦИЯLECTUREМикробиота как новый патогенетический фактор развития хронической гиперурикемии и подагры. Часть I: современное состояние проблемыMicrobiota as a new pathogenetic factor in the development of chronic hyperuricemia and gout. Part I: the current state of the problemhttps://orcid.org/0000-0003-1191-5831ЕлисеевМ. С.EliseevM. S.

Максим Сергеевич Елисеев

115522, Москва, Каширское шоссе, 34А

Maxim S. Eliseev

34A, Kashirskoe Shosse, Moscow 115522

elicmax@yandex.ruhttps://orcid.org/0000-0001-8864-7623ХарламоваЕ. Н.KharlamovaE. N.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-5394-7869ЖелябинаО. В.ZhelyabinaO. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

Кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России

115522, Москва, Каширское шоссе, 34А,

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Department of Rheumatology Russian Medical Academy of Continuing Professional Education

34A, Kashirskoe Shosse, Moscow 115522,

2/1, Barrikadnaya Street, Build. 1, Moscow 125993

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional EducationRussian Federation202218102022165712Copyright © Елисеев М.С., Харламова Е.Н., Желябина О.В., Лила А.М., 20222022Елисеев М.С., Харламова Е.Н., Желябина О.В., Лила А.М.Eliseev M.S., Kharlamova E.N., Zhelyabina O.V., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1339

Микробиота кишечника имеет ключевое значение для метаболизма и иммунной регуляции, а дисбаланс в составе микроорганизмов может способствовать развитию различных заболеваний. Представлены современные данные о роли кишечной микробиоты в возникновении хронической гиперурикемии (ГУ) и подагры, что связано с влиянием микробиоты на синтез пурин-метаболизирующих ферментов и провоспалительных цитокинов. Показано, что микробиота кишечника играет важную роль в патофизиологии подагры и может служить новой мишенью терапии. В настоящее время микробный индекс подагры рассматривается в качестве потенциального метода ранней диагностики заболевания, возможно, уже на преклинической стадии. Микробиота кишечника может стать отправной точкой в изучении патогенеза ГУ и подагры. Это делает необходимым оценку патогенетической связи между отдельными специфическими микроорганизмами, микробиотой в целом и развитием нарушений обмена мочевой кислоты (МК), способствующих возникновению ГУ и трансформации ее в подагру. Предполагается, что данный подход позволит получить более полное представление об участии микробиоты кишечника в синтезе МК и ее внепочечной экскреции, а также о бактериях и бактериальных ферментах, которые могут использоваться в качестве пробиотического коадъюванта для лечения и профилактики подагры.

 

The gut microbiota plays a key role in metabolism and immune regulation, and imbalance in microbial composition can contribute to various diseases. We present up-to-date data on the role of the gut microbiota in the occurrence of chronic hyperuricemia (HU) and gout, which is associated with the influence of the microbiota on the synthesis of purine-metabolizing enzymes and pro-inflammatory cytokines. It has been shown that the gut microbiota plays an important role in the pathophysiology of gout and can serve as a new target for therapy. Currently, the microbial index of gout is considered as a potential method for early diagnosis of the disease, possibly already at the preclinical stage. The gut microbiota can be a starting point in the study of the pathogenesis of HU and gout. This makes it necessary to assess the pathogenetic relationship between individual specific microorganisms, the microbiota as a whole, and the development of uric acid (UA) metabolism disorders that contribute to the onset of HU and its transformation into gout. It is assumed that this approach will provide a more complete understanding of the gut microbiota participation in the synthesis of UA and its extrarenal excretion, as well as of bacteria and bacterial enzymes that can be used as a probiotic coadjuvant for the treatment and prevention of gout.

микробиотаподаграгиперурикемияmicrobiotagouthyperuricemiaReferencesШальнова СА, Деев АД, Артамонова ГВ и др. Гиперурикемия и ее корреляты в Российской популяции (результаты эпидемиологического исследования ЭССЕРФ). Рациональная Фармакотерапия в Кардиологии. 2014;10(2):153-9.Shalnova SA, Deev AD, Artamonov GV, et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Ratsional'naya Farmakoterapiya v Kardiologii. 2014;10(2):153-9. (In Russ.).Барскова ВГ, Елисеев МС, Денисов ИС и др. Частота метаболического синдрома и сопутствующих заболеваний у больных подагрой. Данные многоцентрового исследования. Научно-практическая ревматология. 2012;50(6):15-8.Barskova VG, Eliseev MS, Denisov IS, et al. The rate of metabolic syndrome and comorbidities in patients with gout: data of a multicenter trial. Nauchno-prakticheskaya revmatologiya. 2012;50(6):15-8. (In Russ.).Елисеев МС, Выходец ИТ, Круглова ИВ и др. Распространенность гиперурикемии у профессиональных спортсменов и ее роль в генезе различных патологических состояний и обменных нарушений. Современная ревматология. 2018;12(3):82-8. doi: 10.14412/1996-7012-2018-3-82-88.Eliseev MS, Vykhodets IТ, Kruglova IV, et al. Prevalence of hyperuricemia in professional athletes and its role in the genesis of various pathological conditions and metabolic disturbances. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(3):82-8. (In Russ.). doi: 10.14412/1996-7012-2018-3-82-88.Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016 Oct 22;388(10055):2039- 52. doi: 10.1016/S0140-6736(16)00346-9.Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016 Oct 22;388(10055):2039- 52. doi: 10.1016/S0140-6736(16)00346-9.Mendez-Salazar EO, Martinez-Nava GA. Uric acid extrarenal excretion: the gut microbiome as an evident yet understated factor in gout development. Rheumatol Int. 2022 Mar; 42(3):403-12. doi: 10.1007/s00296-021-05007-x.Mendez-Salazar EO, Martinez-Nava GA. Uric acid extrarenal excretion: the gut microbiome as an evident yet understated factor in gout development. Rheumatol Int. 2022 Mar; 42(3):403-12. doi: 10.1007/s00296-021-05007-x.Salem F, Kindt N, Marchesi JR, et al. Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences. United European Gastroenterol J. 2019 Oct;7(8):1008-32. doi: 10.1177/2050640619867555. Epub 2019 Aug 1.Salem F, Kindt N, Marchesi JR, et al. Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences. United European Gastroenterol J. 2019 Oct;7(8):1008-32. doi: 10.1177/2050640619867555. Epub 2019 Aug 1.Yin J, Sternes PR, Wang M, et al. Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. Ann Rheum Dis. 2020 Jan;79(1): 132-40. doi: 10.1136/annrheumdis-2019-215763. Epub 2019 Oct 29.Yin J, Sternes PR, Wang M, et al. Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. Ann Rheum Dis. 2020 Jan;79(1): 132-40. doi: 10.1136/annrheumdis-2019-215763. Epub 2019 Oct 29.Zhang X, Zhang D, Jiaet H, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med. 2015 Aug;21(8):895-905. doi: 10.1038/nm.3914.Zhang X, Zhang D, Jiaet H, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med. 2015 Aug;21(8):895-905. doi: 10.1038/nm.3914.Scher JU, Ubeda C, Artachoet A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015 Jan; 67(1):128-39. doi: 10.1002/art.38892.Scher JU, Ubeda C, Artachoet A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015 Jan; 67(1):128-39. doi: 10.1002/art.38892.Chu Y, Sun S, Huang Y, et al. Metagenomic analysis revealed the potential role of gut microbiome in gout. NPJ Biofilms Microbiomes. 2021 Aug 9;7(1):66. doi: 10.1038/s41522-021-00235-2.Chu Y, Sun S, Huang Y, et al. Metagenomic analysis revealed the potential role of gut microbiome in gout. NPJ Biofilms Microbiomes. 2021 Aug 9;7(1):66. doi: 10.1038/s41522-021-00235-2.Guo Z, Zhang J, Wang Z, et al. Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep. 2016 Feb 8;6:20602. doi: 10.1038/srep20602.Guo Z, Zhang J, Wang Z, et al. Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep. 2016 Feb 8;6:20602. doi: 10.1038/srep20602.Shao T, Shao L, Li H, et al. Combined signature of the fecal microbiome and metabolome in patients with gout. Front Microbiol. 2017 Feb 21;8:268. doi: 10.3389/fmicb.2017.00268. eCollection 2017.Shao T, Shao L, Li H, et al. Combined signature of the fecal microbiome and metabolome in patients with gout. Front Microbiol. 2017 Feb 21;8:268. doi: 10.3389/fmicb.2017.00268. eCollection 2017.de Oliveira EP, Burini RC. High plasma uric acid concentration: Causes and consequences. Diabetol Metab Syndr. 2012 Apr 4; 4:12. doi: 10.1186/1758-5996-4-12.de Oliveira EP, Burini RC. High plasma uric acid concentration: Causes and consequences. Diabetol Metab Syndr. 2012 Apr 4; 4:12. doi: 10.1186/1758-5996-4-12.Hediger MA, Johnson RJ, Miyazaki H, et al. Molecular physiology of urate transport. Physiology (Bethesda). 2005 Apr;20:125-33. doi: 10.1152/physiol.00039.2004.Hediger MA, Johnson RJ, Miyazaki H, et al. Molecular physiology of urate transport. Physiology (Bethesda). 2005 Apr;20:125-33. doi: 10.1152/physiol.00039.2004.Enomoto A, Kimura H, Chairoungdua A, et al. 2002. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002 May 23;417(6887):447-52. doi: 10.1038/nature742.Enomoto A, Kimura H, Chairoungdua A, et al. 2002. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002 May 23;417(6887):447-52. doi: 10.1038/nature742.Woodward OM, Köttgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10338-42. doi: 10.1073/pnas.0901249106. Epub 2009 Jun 8.Woodward OM, Köttgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10338-42. doi: 10.1073/pnas.0901249106. Epub 2009 Jun 8.Sorensen LB. Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum. 1965 Oct;8(5):694-706. doi: 10.1002/art.1780080429.Sorensen LB. Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum. 1965 Oct;8(5):694-706. doi: 10.1002/art.1780080429.Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012 Apr 3;3:764. doi: 10.1038/ncomms1756.Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012 Apr 3;3:764. doi: 10.1038/ncomms1756.Dalbeth N, Gosling A, Gaffo A, et al. Gout. Lancet. 2021 May 15;397(10287):1843- 1855. doi: 10.1016/S0140-6736(21)00569-9. Epub 2021 Mar 30.Dalbeth N, Gosling A, Gaffo A, et al. Gout. Lancet. 2021 May 15;397(10287):1843- 1855. doi: 10.1016/S0140-6736(21)00569-9. Epub 2021 Mar 30.Crane JK. 2013. Role of host xanthine oxidase in infection due to enteropathogenic and Shiga toxigenic Escherichia coli. Gut Microbes. Sep-Oct 2013;4(5):388-91. doi: 10.4161/gmic.25584.Crane JK. 2013. Role of host xanthine oxidase in infection due to enteropathogenic and Shiga toxigenic Escherichia coli. Gut Microbes. Sep-Oct 2013;4(5):388-91. doi: 10.4161/gmic.25584.Karlsson JL, Barker HA. Tracer experiments on the mechanism of uric acid decomposition and acetic acid synthesis by Clostridium-acidi-urici. J Biol Chem. 1949 Apr;178(2):891-902.Karlsson JL, Barker HA. Tracer experiments on the mechanism of uric acid decomposition and acetic acid synthesis by Clostridium-acidi-urici. J Biol Chem. 1949 Apr;178(2):891-902.Roxon JJ, Ryan AJ, Wright SE. Reduction of tartrazine by a proteus species isolated from rats. Food Cosmet Toxicol. 1966 Aug;4(4):419- 26. doi: 10.1016/s0015-6264(66)80583-7.Roxon JJ, Ryan AJ, Wright SE. Reduction of tartrazine by a proteus species isolated from rats. Food Cosmet Toxicol. 1966 Aug;4(4):419- 26. doi: 10.1016/s0015-6264(66)80583-7.Hsieh CY, Lin HJ, Chen CH, et al. Chronic kidney disease and stroke. Lancet Neurol. 2014 Nov;13(11):1071. doi: 10.1016/S1474-4422(14)70199-1.Hsieh CY, Lin HJ, Chen CH, et al. Chronic kidney disease and stroke. Lancet Neurol. 2014 Nov;13(11):1071. doi: 10.1016/S1474-4422(14)70199-1.Kim HW, Yoon EJ, Jeong SH, et al. Distinct Gut Microbiota in Patients with Asymptomatic Hyperuricemia: A Potential Protector against Gout Development. Yonsei Med J. 2022 Mar;63(3):241-51. doi: 10.3349/ymj.2022.63.3.241.Kim HW, Yoon EJ, Jeong SH, et al. Distinct Gut Microbiota in Patients with Asymptomatic Hyperuricemia: A Potential Protector against Gout Development. Yonsei Med J. 2022 Mar;63(3):241-51. doi: 10.3349/ymj.2022.63.3.241.Wang J, Chen Y, Zhong H, et al. The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies. Crit Rev Food Sci Nutr. 2022;62(14):3979-89. doi: 10.1080/10408398.2021.1874287. Epub 2021 Jan 22.Wang J, Chen Y, Zhong H, et al. The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies. Crit Rev Food Sci Nutr. 2022;62(14):3979-89. doi: 10.1080/10408398.2021.1874287. Epub 2021 Jan 22.Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013 Aug 2;341(6145):569-73. doi: 10.1126/science.1241165. Epub 2013 Jul 4.Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013 Aug 2;341(6145):569-73. doi: 10.1126/science.1241165. Epub 2013 Jul 4.Hosomi A, Nakanishi T, Fujita T, et al. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One. 2012;7(2):e30456. doi: 10.1371/journal.pone.0030456. Epub 2012 Feb 10.Hosomi A, Nakanishi T, Fujita T, et al. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One. 2012;7(2):e30456. doi: 10.1371/journal.pone.0030456. Epub 2012 Feb 10.Patel D, Menon D, Bernfeld E, at al. Aspartate rescues S-phase arrest caused by suppression of glutamine utilization in KRas-driven cancer cells. J Biol Chem. 2016 Apr 22; 291(17):9322-9. doi: 10.1074/jbc.M115.710145. Epub 2016 Feb 26.Patel D, Menon D, Bernfeld E, at al. Aspartate rescues S-phase arrest caused by suppression of glutamine utilization in KRas-driven cancer cells. J Biol Chem. 2016 Apr 22; 291(17):9322-9. doi: 10.1074/jbc.M115.710145. Epub 2016 Feb 26.Tan P, Hyndman D, Miner J. SAT0521 lesinurad, an inhibitor of the Uric acid transporter URAT1 and a potential therapy for gout, requires URAT1 phenylalanine 365 for high affinity inhibition. Ann Rheum Dis. 2014; 73(Suppl 2):780.Tan P, Hyndman D, Miner J. SAT0521 lesinurad, an inhibitor of the Uric acid transporter URAT1 and a potential therapy for gout, requires URAT1 phenylalanine 365 for high affinity inhibition. Ann Rheum Dis. 2014; 73(Suppl 2):780.Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77.Nasonov EL, Eliseev MS. The role of interleukin 1 in the development of human diseases. Nauchno-prakticheskaya revmatologiya. 2016;54(1):60-77. (In Russ.).Елисеев МС. Хроническая болезнь почек: роль гиперурикемии и возможности уратснижающей терапии. Современная ревматология. 2018;12(1):60-5. doi: 10.14412/1996-7012-2018-1-60-65Eliseev MS. Chronic kidney disease: the role of hyperuricemia and the possibility of uratelowering therapy. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(1): 60-5. (In Russ.). doi: 10.14412/1996-7012-2018-1-60-65Singh JA. When gout goes to the heart: does gout equal a cardiovascular disease risk factor? Ann Rheu Dis. 2015 Apr; 74(4):631-4. doi: 10.1136/annrheumdis-2014-206432.Singh JA. When gout goes to the heart: does gout equal a cardiovascular disease risk factor? Ann Rheu Dis. 2015 Apr; 74(4):631-4. doi: 10.1136/annrheumdis-2014-206432.Насонова ВА, Захарова ММ, Барскова ВГ и др. Выявление кристаллов моноурата натрия в биоптатах слизистой оболочки желудка у больных подагрой. Терапевтический архив. 2004;79(6):47-51.Nasonova VA, Zakharova MM, Barskova VG, et al. Detection of sodium monourate crystals in biopsies of gastric mucosa in gout patients. Terapevticheskii arkhiv. 2004;79(6):47-51. (In Russ.).Xu D, Lv Q, Wang X, et al. Hyperuricemia is associated with impaired intestinal permeability in mice. Am J Physiol Gastrointest Liver Physiol. 2019 Oct 1;317(4):G484-G492. doi: 10.1152/ajpgi.00151.2019. Epub 2019 Aug 1.Xu D, Lv Q, Wang X, et al. Hyperuricemia is associated with impaired intestinal permeability in mice. Am J Physiol Gastrointest Liver Physiol. 2019 Oct 1;317(4):G484-G492. doi: 10.1152/ajpgi.00151.2019. Epub 2019 Aug 1.Vaure C, Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front Immunol. 2014 Jul 10;5:316. doi: 10.3389/fimmu.2014.00316. eCollection 2014.Vaure C, Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front Immunol. 2014 Jul 10;5:316. doi: 10.3389/fimmu.2014.00316. eCollection 2014.Perry RJ, Peng L, Barry NA, et al. Acetate mediates a microbiome-brain-β cell axis promoting metabolic syndrome. Nature. 2016 Jun 9;534(7606):213-7. doi: 10.1038/nature18309.Perry RJ, Peng L, Barry NA, et al. Acetate mediates a microbiome-brain-β cell axis promoting metabolic syndrome. Nature. 2016 Jun 9;534(7606):213-7. doi: 10.1038/nature18309.Vieira AT, Macia L, Galvaoet I, et al. A role for gut microbiota and the metabolitesensing receptor GPR43 in a murine model of gout. Arthritis Rheumatol. 2015 Jun;67(6): 1646-56. doi: 10.1002/art.39107.Vieira AT, Macia L, Galvaoet I, et al. A role for gut microbiota and the metabolitesensing receptor GPR43 in a murine model of gout. Arthritis Rheumatol. 2015 Jun;67(6): 1646-56. doi: 10.1002/art.39107.Tannahill, GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature. 2013 Apr 11; 496(7444):238–42. doi: 10.1038/nature11986.Tannahill, GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature. 2013 Apr 11; 496(7444):238–42. doi: 10.1038/nature11986.Raspe C, Czeslick E, Weimann A, et al. Glutamine and alanine-induced differential expression of intracellular IL-6, IL-8, and TNF-α in LPS-stimulated monocytes in human whole blood. Cytokine. 2013 Apr;62(1): 52-7. doi: 10.1016/j.cyto.2013.02.020.Raspe C, Czeslick E, Weimann A, et al. Glutamine and alanine-induced differential expression of intracellular IL-6, IL-8, and TNF-α in LPS-stimulated monocytes in human whole blood. Cytokine. 2013 Apr;62(1): 52-7. doi: 10.1016/j.cyto.2013.02.020.Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006 Mar 9; 440(7081):237-41. doi: 10.1038/nature04516.Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006 Mar 9; 440(7081):237-41. doi: 10.1038/nature04516.Kilgore M, Miller CA, Fass DM, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2010 Mar;35(4):870-80. doi: 10.1038/npp.2009.197. Epub 2009 Dec 9.Kilgore M, Miller CA, Fass DM, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2010 Mar;35(4):870-80. doi: 10.1038/npp.2009.197. Epub 2009 Dec 9.Cleophas MC, Crisan TO, Lemmers H, et al. Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases. Ann Rheum Dis. 2016 Mar;75(3): 593-600. doi: 10.1136/annrheumdis-2014-206258. Epub 2015 Jan 14.Cleophas MC, Crisan TO, Lemmers H, et al. Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases. Ann Rheum Dis. 2016 Mar;75(3): 593-600. doi: 10.1136/annrheumdis-2014-206258. Epub 2015 Jan 14.Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005 Jun 10;308(5728):1635-8. doi: 10.1126/science.1110591. Epub 2005 Apr 14.Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005 Jun 10;308(5728):1635-8. doi: 10.1126/science.1110591. Epub 2005 Apr 14.Tamanai-Shacoori Z, Smida I, Bousarghin L, et al. Roseburia spp.: a marker of health? Future Microbiol. 2017 Feb;12:157-70. doi: 10.2217/fmb-2016-0130.Tamanai-Shacoori Z, Smida I, Bousarghin L, et al. Roseburia spp.: a marker of health? Future Microbiol. 2017 Feb;12:157-70. doi: 10.2217/fmb-2016-0130.Li G, Yao W, Jiang H. Short-chain fatty acids enhance adipocyte differentiation in the stromal vascular fraction of porcine adipose tissue. J Nutr. 2014 Dec;144(12):1887-95. doi: 10.3945/jn.114.198531. Epub 2014 Oct 15.Li G, Yao W, Jiang H. Short-chain fatty acids enhance adipocyte differentiation in the stromal vascular fraction of porcine adipose tissue. J Nutr. 2014 Dec;144(12):1887-95. doi: 10.3945/jn.114.198531. Epub 2014 Oct 15.Park HK, Lee SJ. Treatment of gouty arthritis is associated with restoring the gut microbiota and promoting the production of short-chain fatty acids. Arthritis Res Ther. 2022 Feb 19;24(1):51. doi: 10.1186/s13075-022-02742-9.Park HK, Lee SJ. Treatment of gouty arthritis is associated with restoring the gut microbiota and promoting the production of short-chain fatty acids. Arthritis Res Ther. 2022 Feb 19;24(1):51. doi: 10.1186/s13075-022-02742-9.Kebir DEL, Filep JG. Role of neutrophil apoptosis in the resolution of inflammation. ScientificWorldJournal. 2010 Sep 1;10:1731- 48. doi: 10.1100/tsw.2010.169.Kebir DEL, Filep JG. Role of neutrophil apoptosis in the resolution of inflammation. ScientificWorldJournal. 2010 Sep 1;10:1731- 48. doi: 10.1100/tsw.2010.169.Dalbeth N, Choi HK, Joosten LAB, et al. Gout. Nat Rev Dis Primers. 2019 Sep 26;5(1): 69. doi: 10.1038/s41572-019-0115-y.Dalbeth N, Choi HK, Joosten LAB, et al. Gout. Nat Rev Dis Primers. 2019 Sep 26;5(1): 69. doi: 10.1038/s41572-019-0115-y.Kuo YW, Hsieh SH, Chen JF, et al. Lactobacillus reuteri TSR332 and Lactobacillus fermentum TSF331 stabilize serum uric acid levels and prevent hyperuricemia in rats. PeerJ. 2021 May 3;9:e11209. doi: 10.7717/peerj.11209. eCollection 2021.Kuo YW, Hsieh SH, Chen JF, et al. Lactobacillus reuteri TSR332 and Lactobacillus fermentum TSF331 stabilize serum uric acid levels and prevent hyperuricemia in rats. PeerJ. 2021 May 3;9:e11209. doi: 10.7717/peerj.11209. eCollection 2021.Wang H, Mei L, Deng Y, et al. Lactobacillus brevis DM9218 ameliorates fructose-induced hyperuricemia through inosine degradation and manipulation of intestinal dysbiosis. Nutrition. 2019 Jun;62:63-73. doi: 10.1016/j.nut.2018.11.018. Epub 2018 Nov 26.Wang H, Mei L, Deng Y, et al. Lactobacillus brevis DM9218 ameliorates fructose-induced hyperuricemia through inosine degradation and manipulation of intestinal dysbiosis. Nutrition. 2019 Jun;62:63-73. doi: 10.1016/j.nut.2018.11.018. Epub 2018 Nov 26.Yamazaki T, Ohshio K, Sugamata M, Morita Y. Lactic acid bacterium, Lactobacillus paracasei KW3110, suppresses inflammatory stress-induced caspase-1 activation by promoting interleukin-10 production in mouse and human immune cells. PLoS One. 2020 Aug 17; 15: e0237754. doi: 10.1371/journal.pone. 0237754. eCollection 2020.Yamazaki T, Ohshio K, Sugamata M, Morita Y. Lactic acid bacterium, Lactobacillus paracasei KW3110, suppresses inflammatory stress-induced caspase-1 activation by promoting interleukin-10 production in mouse and human immune cells. PLoS One. 2020 Aug 17; 15: e0237754. doi: 10.1371/journal.pone. 0237754. eCollection 2020.Suzuki H, Yamazaki T, Ohshio K, et al. A specific strain of lactic acid bacteria, lactobacillus paracasei, inhibits inflammasome activation in vitro and prevents inflammationrelated disorders. J Immunol. 2020 Aug 1;205 (3):811-21. doi: 10.4049/jimmunol.1900657.Suzuki H, Yamazaki T, Ohshio K, et al. A specific strain of lactic acid bacteria, lactobacillus paracasei, inhibits inflammasome activation in vitro and prevents inflammationrelated disorders. J Immunol. 2020 Aug 1;205 (3):811-21. doi: 10.4049/jimmunol.1900657.Joosten LA, Netea MG, Mylona E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1 production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 2010 Nov;62(11): 3237-48. doi: 10.1002/art.27667Joosten LA, Netea MG, Mylona E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1 production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 2010 Nov;62(11): 3237-48. doi: 10.1002/art.27667

The authors declare that there are no conflicts of interest present.